$CYCN News
Last published 1d ago
- 1d agoCYCNSTIFEL 2026 HEALTHCARE CONFERENCE - KORSANA BIOSCIENCES INCEarnings Call TranscriptsThanks. Thanks very much, everybody. Happy to hear moderating a fireside chat with Jonathan Violin, president and CEO of Corsana Biosciences. You know, some folks listening may be new to the story. So I was kind of think
- 2d agoCYCNKorsana Biosciences, Inc. (KRSA) - Guggenheim 3rd Annual Healthcare Innovation Conference - KORSANA BIOSCIENCES INCEarnings Call TranscriptsGood morning. We should be live now. Welcome to Guggenheim Third Annual Healthcare Innovation Conference. My name is Yatin Suneja, one of the biotech analysts here. I'm joined here by my colleague, Delma Kayati. So our n
- 2mo agoCYCNANNUAL MEETING OF SHAREHOLDERS - CYCLERION THERAPEUTICS INCEarnings Call TranscriptsThank you for watching. Thank you. Thank you for watching. Thank you. Thank you. Thank you. Thank you for watching. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. © transcript Emily Beynon T
- 2mo agoCYCNANNUAL MEETING OF SHAREHOLDERS - CYCLERION THERAPEUTICS INCEarnings Call TranscriptsThank you for watching. Thank you. Thank you for watching. Thank you. Thank you. Thank you. Thank you for watching. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. © transcript Emily Beynon T
- 7mo agoCYCNCyclerion Therapeutics and Korsana Biosciences Announce Merger AgreementBusiness WireCombined company to operate as Korsana Biosciences and to advance Korsana's potential best-in-class therapeutics to treat neurodegenerative diseases Korsana's lead program KRSA-028 is a next-generation shuttled
- 8mo agoCYCNCyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory BoardGlobeNewswire–Received Positive Pre-Investigational New Drug ("IND") Written Feedback from the U.S. Food and Drug Administration ("FDA")– –Clinical Advisory Board ("CAB") Includes Key Leaders across Neuropsychiatry,
- 10mo agoALMSBFRGCYCNKBLBMorning Market Brief: Breakthrough Biology Meets Scalable Platforms as Innovators Surge into FocusGlobeNewswireDENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a clear appetite for substance over speculation, as investors gravitate toward companies delivering late-stage clinical wins, scalable science, and
- 10mo agoCYCNCyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant DepressionGlobeNewswire– Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept ("POC")
- 1y agoCYCNCyclerion Announces Transformational Relaunch as a Neuropsychiatric CompanyGlobeNewswire– Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement – – Webcast to be held September 24, 2025 at 10:30 a.m. ET – CAMBRIDGE,
- 1y agoCYCNCyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company GrowthGlobeNewswireCAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), today announced an update on its progress in catalyzing the Company's next stage of growth. The Company is leveraging its
- 2y agoCYCNRegina Graul, Ph.D., Promoted to Chief Executive OfficerGlobeNewswireCAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), today announced that Regina Graul, Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board
- 2y agoCYCNCyclerion Appoints Regina Graul, Ph.D., as PresidentGlobeNewswire– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to
- 2y agoCYCNCyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge InnovatorGlobeNewswire- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric
- 3y agoCYCNTisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion AssetsGlobeNewswire– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease with No Approved
- 3y agoCYCNCyclerion Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireCAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. ("Cyclerion" or the "Company") (NASDAQ:CYCN) today announced that it has received a formal notice from The Nasdaq Stock Market (Nasdaq)
- 3y agoCYCNCyclerion Announces Reverse Stock SplitGlobeNewswireCAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the "Company", "Cyclerion Therapeutics", "Cyclerion") (NASDAQ:CYCN) announced today that it will effect a reverse stock split of its
- 3y agoCYCNCyclerion Announces Definitive Agreement for Zagociguat and CY3018GlobeNewswireCertain Cyclerion shareholders and new investors have agreed to invest $81M to launch a new company targeting diseases of mitochondrial dysfunction Cyclerion to receive $8M in cash and 10% equity in the new company in
- 3y agoCYCNCyclerion Announces Corporate Updates and Q1 2023 Financial ResultsGlobeNewswireDefinitive agreement reached with new company ("NewCo") established by certain Cyclerion shareholders and new investors Cyclerion to receive $8M in cash and 10% equity in NewCo in exchange for its zagociguat and CY3018
- 3y agoCYCNCyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment AgreementGlobeNewswireCAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) today announced that the Board of Directors of the Company, acting solely by all of its independent and disinterested
- 3y agoCYCNCyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial DiseasesGlobeNewswireCAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that
- 3y agoCYCNCyclerion Reports Corporate Update and Full Year 2022 Financial ResultsGlobeNewswireCAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) today announced corporate updates including advances in its zagociguat (formerly CY6463) mitochondrial disease program.
- 3y agoCYCNCyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The CompanyGlobeNewswireCAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) today announced that the Board of Directors of the Company acting solely by all of its independent and disinterested
- 4y agoCYCNCyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial ResultsGlobeNewswirePositive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associated with Schizophrenia (CIAS) Study in Alzheimer
- 4y agoCYCNCyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)GlobeNewswireStudy data demonstrate positive effects of CY6463 on cognition and inflammation after two weeks of dosing in patients with stable schizophrenia on standard of care Oral, once-daily CY6463 was well tolerated, with no reports of serious adverse events (
- 4y agoCYCNSteven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of Steven E.
- 4y agoCYCNCyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease FoundationGlobeNewswireData for CY6463, a first-in-class, CNS-penetrant, sGC stimulator, demonstrate safety and positive effects across biomarkers of disease in MELAS patients Company leadership discussed key insights for patients with MELAS with clinician-researcher, Amel
- 4y agoCYCNCyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease FoundationGlobeNewswireCompany to discuss positive topline and additional clinical data for CY6463 in MELAS patients Mitochondrial disease clinician-researcher, Amel Karaa, M.D., to discuss the potential future impact on patients Webcast scheduled for Tuesday, June 28th
- 4y agoCYCNCyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial DiseaseGlobeNewswireCY6463 alleviated mitochondrial dysfunction and reduced inflammation in preclinical models of mitochondrial complex 1 deficiency Data provide support for ongoing CY6463 clinical studies in CNS diseases associated with mitochondrial dysfunction CAMB
- 4y agoCYCNCyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 SymposiumGlobeNewswireData from an eight-patient, open-label study demonstrate improvements across multiple biomarkers of mitochondrial function, inflammation, cerebral blood flow, and functional connectivity CY6463 was well tolerated, with no reports of serious advers
- 4y agoCYCNCyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 SymposiumGlobeNewswireTopline results to be shared during the clinical trial update platform session CHOP preclinical data demonstrates CY6463-induced functional improvement in zebrafish disease models CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Cyclerion Ther
- 4y agoCYCNCyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial ResultsGlobeNewswireCharacterizing the novel neuropharmacology of CY6463's NO-sGC-cGMP signal modulation in an integrated clinical strategy currently involving three ongoing, exploratory, biomarker-rich, signal seeking studies: Mitochondrial Encephalomyopathy, Lactic
- 4y agoCYCNCyclerion Announces CY6463 Clinical Pipeline and Corporate UpdatesGlobeNewswirePhase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022 Phase 1b study in Cognitive Impairment Associated with Schizophrenia (CIAS) enrollment on
- 4y agoCYCNCyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine CollaborationGlobeNewswireCAMBRIDGE, Mass. and PARIS, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) and Ariana Pharma today announced an artificial intelligence-driven, precision medicine collaboration. This collaboration is expected to identify b
- 4y agoCNTGCYCNCENTOGENE Announces Nomination of Andreas Busch to Supervisory BoardGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced t
- 4y agoCYCNCyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer's Disease with Vascular PathologyGlobeNewswireCAMBRIDGE, Mass., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that patient dosing has begun
- 5y agoCYCNCyclerion Therapeutics to Participate in Jefferies London Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that management will attend t
- 5y agoCYCNCyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate UpdateGlobeNewswireFirst patients enrolled in study in Cognitive Impairment Associated with Schizophrenia (CIAS) Patient screening underway in study in Alzheimer's disease with vascular pathology (ADv) Enrollment ongoing in study in Mitochondrial Encephalomyopathy, L
- 5y agoCYCNFINVICCMSESN+1Thinking about buying stock in Sesen Bio, FinVolution Group, Valneva SE, Cyclerion Therapeutics, or Icecure Medical?PR NewswireNEW YORK, Oct. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SESN, FINV, VALN, CYCN, and ICCM.
- 5y agoCYCNCyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC StimulatorGlobeNewswireCAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company developing treatments that restore cognitive function, today announced a publication demonstrating that administ
- 5y agoCYCNCyclerion Therapeutics to Participate in Two Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Company management will
- 5y agoCYCNCyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease SummitGlobeNewswireCAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced participation in the Annual B
- 5y agoCYCNCyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate UpdateGlobeNewswireContinuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive impairment Advancing CY3018, a differentiated,
- 5y agoCYCNCyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer's Disease with Vascular Pathology at the Alzheimer's Association International Conference 2021 (AAIC)GlobeNewswireCAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that it will present clinical
- 5y agoCYCNBeacon Biosignals and Cyclerion Therapeutics Announce Strategic PartnershipPR NewswireBOSTON, July 8, 2021 /PRNewswire/ -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies. This collaboration is expected to identify disease-relevant
- 5y agoCYCNCyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic PartnershipGlobeNewswireCAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies. This collaboration is expected to identify di
- 5y agoCYCNCyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for PraliciguatGlobeNewswireCyclerion eligible to receive up to $585 million in potential future development and commercial milestone payments, and tiered sales-based royalties Praliciguat out-licensing further enables Cyclerion's strategic focus on CNS, including first-in-class
- 5y agoCYCNCyclerion Therapeutics Announces $18 Million Private PlacementGlobeNewswireCAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced a direct private sale of ap
- 5y agoCYCNCyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in PharmacologyGlobeNewswireSeries of preclinical studies demonstrate the therapeutic potential of CY6463, a first-in-class, CNS-penetrant sGC stimulator Oral, once-daily CY6463 is being developed for neurological diseases associated with cognitive impairment CAMBRIDGE, Mass.
- 5y agoCYCNCyclerion Therapeutics to Participate in Jefferies Virtual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) today announced that Company management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m.
- 5y agoCYCNCyclerion Therapeutics Hosted Webinar to Discuss Pipeline ProgressGlobeNewswireProvided updates on development strategy and execution for CY6463, a first-in-class, CNS-penetrant sGC stimulator, including IND clearance from FDA in ADv and ongoing MELAS program Introduced new CY6463 clinical program in CIAS with k